Is there a rationale to supplement hepatotropic factors to dogs with multiple acquired portosystemic shunts secondary to congenital portosystemic shunt attenuation?

Is er wetenschappelijke basis om hepatotrope factoren te supplementeren aan honden met multiple verworven portosystemische shunts secundair aan attenuatie van een congenitale portosystemische shunt?

1L.Van Acker, 1H. de Rooster, 1G. Serrano, 1D. Paepe, 2W. De Spiegelaere, 1N. Devriendt

1Department of Small Animals, Faculty of Veterinary Medicine, Ghent University, Salisburylaan 133, 9820 Merelbeke, Belgium
2Department of Morphology, Faculty of Veterinary Medicine, Ghent University, Salisburylaan 133, 9820 Merelbeke, Belgium

hilde.derooster@ugent.be

ABSTRACT

Experimental rat models and clinical trials in human patients with liver cirrhosis show evidence that supplementation with hepatotropic factors provides therapeutic benefits. This form of support has not yet been described in dogs with multiple acquired portosystemic shunts (MAPSS) despite similarities between both pathological conditions. Especially hepatocyte growth factor (HGF) and branched chain amino acids (BCAA) deserve closer attention. High-quality vegetable rather than animal proteins have been suggested to form an excellent dietary source of BCAA, and leucine seems the best candidate for supplementation given its stimulating effects on liver function in general and on HGF secretion specifically. Research on optimal ways of administration of HGF in dogs with MAPSS secondary to congenital portosystemic shunt attenuation is necessary before clinical trials can be initiated.

SAMENVATTING

Experimentele proeven met ratten en klinische proeven met humane patiënten met levercirrhoze tonen aan dat supplementatie met hepatotrope factoren therapeutische voordelen biedt. Bij honden met multiple verworven portosystemische shunts werd een dergelijke supplementatie nog niet beschreven, ondanks gelijkenissen tussen beide aandoeningen. Vooral de effecten van “hepatocyte growth factor” (HGF) en vertakte keten aminozuren (BCAA) verdienen bijzondere aandacht. Hoogkwalitatieve plantaardige eiwitten, eerder dan dierlijke, worden naar voor geschoven als uitstekende bron van BCAA in de voeding. Leucine blijkt de beste kandidaat voor supplementatie gezien haar stimulatie van leverfunctie in het algemeen, en meer specifiek haar stimulatie van HGF-secretie. Verder onderzoek naar optimale toedieningswegen van HGF bij honden met multiple verworven portosystemische shunts secundair aan attenuatie van een congenitale portosystemische shunt, is nodig vooraleer klinische proeven kunnen aangevat worden.

INTRODUCTION

Multiple acquired portosystemic shunts (MAPSS) have been described in various species including humans and dogs. Traditionally, they are considered to be a collection of embryonic vessels between the portal and systemic circulation, opening as a consequence of portal hypertension (Johnson, 1987; Berent and Tobias, 2009; Buob et al., 2011; Lipinski et al., 2018; Ramirez et al., 2019). More recently, de novo formation of collateral vessels through active neo-angiogenesis has been recognized as a different but
complementary mechanism in portal hypertension (Garcia-Pras et al., 2017; Ramirez et al., 2019). Portal hypertension, or increased blood pressure in the portal vein, can be caused by an increased resistance within the portal circulation, in case of cirrhosis of the liver or portal vein thrombosis, and/or an increased portal blood volume (Berent and Tobias, 2009; Bosch et al., 2010; Buob et al., 2011; Ramirez et al., 2019). An idiopathic noncirrhotic form of portal hypertension has also been described in dogs (Bunch et al., 2001). In an experimental canine model of portal hypertension, MAPSS developed as early as four weeks after the administration of a hepatotoxin that induced hepatic fibrosis and cirrhosis (Howe et al., 2000). The emergence of MAPSS might initially normalize the portal vein pressure; however, if the underlying hepatopathy persists or progresses, portal hypertension might redevelop since progressive vasodilation of the gastrointestinal vasculature will result in a progressive increase in portal blood flow (Buob et al., 2011; Ramirez et al., 2019). Additionally, pathological vascular endothelial growth factor (VEGF)-driven angiogenesis in hypoxic splanchic organs contributes to increased portal blood flow (Bosch et al., 2010; Ramirez et al., 2019).

Although the correlation of cirrhosis and MAPSS has been described in dogs (Boothe et al., 1996), in the majority of publications dealing with MAPSS, dogs have been described with a history of a congenital portosystemic shunt (CPSS) that has been surgically treated (Berent and Tobias, 2009; Serrano et al., 2019). The infrequent use of sensitive imaging modalities during the postoperative follow-up (Serrano et al., 2019) leaves us with an imprecise estimation of the actual incidence of MAPSS following surgical attenuation of CPSS. This might explain the lack of guidelines concerning the management of postoperative MAPSS other than the suggestion that most dogs with MAPSS most likely benefit from life-long medical management including adjusted diet, and/or lactulose and/or (temporary) antimicrobial treatment (Boothe et al., 1996). The persistent aberrant hepatic perfusion will preclude that the liver efficaciously detoxifies the blood from substances such as ammonia whereas the hepatocytes will lose their proliferative state and fail to produce adequate amounts of substances normally provided by the liver, such as albumin and clotting factors (Suter, 1975; Johnson, 1987; Kruitwagen et al., 2011; Zwingenberger et al., 2014). Hypoalbuminemia has various consequences for patients with cirrhosis and/or MAPSS. Ascites, present as a consequence of portal hypertension, can be further aggravated by hypoalbuminemia as the drop in vascular colloid osmotic pressure drives fluid into the interstitial space (Hou and Sanyal, 2009). Hypoalbuminemia also increases the severity of hepatic encephalopathy (HE), because otherwise protein-bound encephalogenic substances such as aromatic amino acids (AAA) might have easier access to the brain (Greco et al., 2000). Low albumin levels also negatively affect the antioxidant activity as well as the capacity to bind fatty acids, bilirubin, hormones, toxic substances and other ligands (Nicholson et al., 2000).

Both MAPSS and cirrhosis can be linked to impairment of liver function and other signs of chronic liver diseases (Rothuizen, 1993; Taboada and Dimski, 1995; Buob et al., 2011; Cullen and Stalker, 2015). Therefore, treatment strategies based on hepatotropic factors might, to some extent, be beneficial to dogs with MAPSS for whom, up to date, only supportive management has been considered. A canine in vivo model to screen for various putative hepatotropic growth factors identified hepatocyte growth factor (HGF), insulin-like growth factor II (IGF-II), transforming growth factor-α (TGF–α), and hepatic stimulatory substance (HSS) as growth hormones with striking hepatotropic qualities (Francavilla et al., 1991). Whereas a lot of information is available on HGF, the paucity of studies dealing with the remainder of the factors unfortunately precludes a thorough review of their potential in dogs with MAPSS.

In this viewpoint article, HGF and BCAA will be described with respect to their activity, expected benefits and potential side effects in dogs. Hepatocyte growth factor is a protein that has mitogenic (Nakamura et al., 1984; Nakamura et al., 1989) and anti-apoptotic effects (Kim et al., 2005) on hepatocytes and exogenous HGF is under research as a liver regenerative drug in humans (Mizuno and Nakamura, 2007; Nakamura and Mizuno, 2010). Likewise, the benefits of oral supplementation of BCAA in liver regeneration seem manifold and include providing an efficient energy source (Kato et al., 1998), triggering mobilization and transformation of stem cells into hepatocytes (Okabayashi et al., 2014), and increasing the secretion of HGF (Tomiyama et al., 2002; Tomiyama et al., 2004) and albumin levels (Yoshida et al., 1989; Kato et al., 1991).

In dogs with MAPSS, the majority of components entering the portal vein caudal to the shunts directly reaches the systemic circulation, leaving only a small fraction of the desired substance to be delivered to first-pass effect in the liver. Therefore, apart from identifying appropriate hepatotropic factors, defining the most appropriate route of supplementation to reach the liver or reside in the liver at adequate concentration is the major challenge in dogs with MAPSS.

Before addressing available research data in dogs, a synthesis concerning data gained in rats and human patients with liver disease will be made as most research on hepatotropic factors is performed in cell lines, experimental in vivo models and in human clinical trials rather than in dogs.

**HEPATOCYTE GROWTH FACTOR**

Hepatocyte growth factor is produced in mesenchymal stromal cells and has mitogenic capacity; it has been identified as a protein that encourages initia-
HGF can stimulate albumin synthesis in hepatocytes as indicated by in vitro experiments of hepatocytes stimulated with recombinant human (rh)-HGF (Takehara et al., 1992) and in vivo after intravenous administration of rh-HGF to healthy rats (Yamaoka et al., 1998; Ishii et al., 1995). While HGF additionally exerts anti-apoptotic effects on hepatocytes, its pro-apoptotic effects on portal myofibroblasts, which are phenotypically changed hepatic stellate cells that synthesize proteins that induce fibrosis (Wu and Zern, 2000), have been proven in in vivo rat models (Kim et al., 2005). Furthermore, HGF suppresses the proliferation of those portal myofibroblasts by inhibiting DNA synthesis (Kim et al., 2005). While liver cirrhosis is generally thought to be an irreversible condition, an in vivo dimethylnitrosamine rat model of lethal liver cirrhosis has shown that resolution from liver cirrhosis is possible with remodeling of excess extracellular matrix after intraperitoneal rh-HGF administration (Kim et al., 2005). One week after daily intraperitoneal HGF injections, fibrous tissue areas were reduced by 60% compared to the fibrous tissue areas of rats given saline injections as sham controls (Kim et al., 2005).

The most common supplementation route of exogenous HGF with the aim of liver regeneration in rodents is intravenous injection of rh-HGF (Ishiki et al., 1992; Fujiwara et al., 1993). Alternatively, intraperitoneal administration of HGF (Kim et al., 2005) and transfections of the human HGF gene into skeletal muscles of rats have also been shown to effectively treat induced liver cirrhosis (Ueki et al., 1999).

Despite interest in HGF as a liver regenerative drug (Mizuno and Nakamura, 2007; Nakamura and Mizuno, 2010), clinical trials have not yet been initiated in humans.

**Hepatocyte growth factor in dogs: challenges to achieve long-term effects**

The effect of exogenous rh-HGF on liver regeneration has been studied in experimental beagle dogs subjected to left-sided portal branch ligation (Ueno et al., 1996). Two days after this procedure, rh-HGF was administered directly into the portal vein through a central venous catheter. Considerable liver growth was observed during three weeks of intravenous treatment (Kruitwagen et al., 2011). Although liver volume did increase significantly during the period of HGF administration, the treatment result was only temporary, suggesting that lifelong HGF supplementation would be needed to result in sustained liver growth (Kruitwagen et al., 2011). Importantly, the increase in liver size did not result in normalization of the serum albumin levels, neither did liver function tests improve, probably because portal perfusion did not change in the presence of the CPSS (Kruitwagen et al., 2011).

Since patients with MAPSS due to prehepatic or hepatic pathologies are often characterized by an underdeveloped liver, the idea of HGF supplementation to those patients triggers further research. Similar to the situation in dogs with a CPSS (Kruitwagen et al., 2011), it is unlikely that intravenous HGF supplementation would have a positive effect on the albumin concentrations in dogs with MAPSS. Nevertheless, it is certainly interesting to explore alternative ways of administration and/or potentially alternative forms of HGF such as prolonged release formulations of HGF analogues. Administration of rh-HGF is well tolerated by dogs (Ueno et al., 1996), whereas recombinant feline HGF induces an immunological reaction in dogs (Kruitwagen et al., 2011). Producing large amounts of rh-HGF for therapeutic purposes would not be a limiting factor since it can be provided by ex vivo in a plasmid vector selection and cloning processes (Strain et al., 1991), which is presumed to be similar for recombinant canine HGF. A possible alternative to rh-HGF would be the administration of drugs which stimulate endogenous HGF release (Borawski et al., 2007) and can be administered orally, eliminating the necessity of a venous catheter. An additional challenge in dogs with MAPSS would be whether the hypoperfused hepatocytes can be sufficiently triggered. Likewise, it would be interesting to explore the role of pro-inflammatory cytokines and humoral mediators in the production of HGF as disease-modulating agents (Nakamura and Mizuno, 2010). In this way, alternative pathways to ensure higher endogenous HGF levels may be ascertained.

**BRANCHED CHAIN AMINO ACIDS**

Branched chain amino acids, such as leucine, isoleucine and valine, are essential amino acids in mammals, meaning – in the strict sense – that they form a dietary necessity and cannot be synthesized de novo (Reeds, 2000). However, they can be synthesized by transamination of their branched chain keto acid analogues; yet, these keto acid analogues were originally derived from the BCAA themselves (Reeds, 2000). It is therefore mandatory to provide sufficient dietary intake of BCAA.

In humans with liver cirrhosis, BCAA offer a high-
er energy efficacy than glucose or fatty acids (Kato et al., 1998). In several studies in human patients and rats undergoing partial hepatectomy, an effect of BCAA supplementation has also been reported on liver regeneration (Kim et al., 2011; Beppu et al., 2015). Supplementation of BCAA is also known to increase albumin concentrations in humans with liver cirrhosis (Yoshida et al., 1989; Kato et al., 1991).

In humans with liver disease resulting in hyperammonemia, plasma concentrations of BCAA are severely decreased (Soeters and Fischer, 1976) because these amino acids are intensely consumed by an alternate route of ammonia detoxification, forming glutamine in muscle and brain tissue (Bachmann et al., 2004; Holecek et al., 2011). In case of malnutrition, muscle tissue catabolism is increased, disturbing this alternate route. The brain then becomes the main source of glutamine synthesis, leading to astrocyte swelling and more severe HE (Brusilow and Trastman, 1986; Bachmann et al., 2004; Cohn and Roth, 2004). Additionally, the lack of ammonia detoxification in muscle tissue leads to more accumulation of ammonia in the blood, which will further increase utilization of BCAA, causing even lower BCAA levels (Bachmann et al., 2004). In order to maintain lean body mass and thus preserve sufficient glutamine synthesis in muscle tissue to avoid this vicious circle, patients with liver cirrhosis must be provided with a diet containing high quality proteins (Plauth et al., 1997a; Plauth et al., 1997b; Merli and Riggio, 2009). In dogs with PSS, daily ingestion of 2.11 g crude protein/kg body weight with an 80% or greater availability is recommended to adequately maintain body protein reserves without inciting HE (Laflamme et al., 1993). Vegetable proteins are suggested to result in less severe HE compared to animal proteins, since they ameliorate the nitrogen balance and contain higher levels of BCAA (Keshavarzian et al., 1984; Bianchi et al., 1993).

In many studies in human patients with liver cirrhosis and HE, clinical improvement after administration of BCAA-enriched diets has been reported (Marchesini et al., 1990; Bianchi et al., 1992; Plauth et al., 1993). It must be noted that the supplementation route can strongly influence the effects of BCAA. Although there is no complete certainty on preferable supplementation routes, oral administration of BCAA (whether or not in combination with lactulose) has been shown to significantly improve the manifestation of HE in humans with liver cirrhosis, whereas intravenous administration seems to have lesser effects on HE (Gluud et al., 2013a; Gluud et al., 2013b). There are indications that the amelioration of HE signs is explained by an increased ratio of BCAA to AAA, such as phenylalanine, tryptophan and tyrosine, rather than by the reduction of blood ammonia levels (Tajiri and Shimizu, 2013). Next to the route, the timing of BCAA supplementation influences the effect size; administration of a double dose of BCAA before bedtime versus one dose at lunch and one at dinner improves the serum albumin levels, even in refractory cirrhotic patients (Fukushima et al., 2003).

Leucine seems to be the most suitable candidate for supplementation in case of liver disease, as has been put forward in studies on hepatic stellate cell culture and in rats in vivo, because it also stimulates the secretion of HGF, in contrast to isoleucine or valine (Tomiya et al., 2002; Tomiya et al., 2004). In young growing rats, intraperitoneal injections of leucine increase HGF secretion and, after repeated treatments, an increase in liver weight has been observed (Tomiya et al., 2004). Additionally, adult healthy rats have shown increased serum albumin concentrations, indicating a clear improvement in liver function (Tomiya et al., 2004). Leucine is particularly interesting since it does not form a complex with albumin mRNA, leaving albumin mRNA free for translation (Kuwahata et al., 2008). The effects of leucine supplementation in rats with liver cirrhosis remain to be studied.

**Do branched chain amino acids have hepatotropic properties in dogs with liver disease?**

In several studies, a reduced ratio of BCAA to AAA has been confirmed in dogs with liver disease (Aguirre et al., 1974; Joyeux et al., 1994; Awad et al., 2000). Nevertheless, there is no literature available on the effects of BCAA supplementation in dogs with severe hepatopathy, with the exception of one experimental cross-over study, in which a portocaval shunt was created followed by partial hepatectomy (Meyer et al., 1999). In that study, the dogs showed a significant decrease in BCAA, a concomitant rise in AAA, hyperammonemia, and obvious signs of HE after these interventions (Meyer et al., 1999). After this model had been created, the dogs received either a diet with high BCAA/AAA ratio or a diet with low BCAA/AAA ratio; both diets contained the same protein amount and were fed ad libitum (Meyer et al., 1999). Unexpectedly, the dogs had a lower plasma ammonia concentration when eating the low BCAA/AAA ratio diet, of which they consumed significantly more than of the high ratio diet. In that study, it was concluded that not the proportion of amino acids in a diet but rather the total protein intake, and therefore, the overall improved nutritional state, could possibly be responsible for decreasing HE symptoms (Meyer et al., 1999). Remarkably, there was no normalization of the BCAA/AAA ratio in the dogs given the high ratio diet, suggesting a higher peripheral utilization of BCAA (Meyer et al., 1999). Interestingly, Proot et al. (1999) compared the use of a soy protein diet versus a poultry protein diet in dogs with PSS and concluded that the significantly lower blood ammonia concentrations after the soy protein diet were more likely to be related to the higher digestibility of that protein source than to its better BCAA/AAA ratio. In a study in rats with experimentally induced PSS, it has been
documented that a soy protein diet prevents hypermetamnia, lowering the risk of ammonia toxic effects (Shimooka et al., 2006). Further research remains necessary to evaluate whether or not BCAA alleviate clinical signs of HE and have hepatotrophic properties in dogs with severe liver disease and/or MAPSS. In particular, the effects of leucine on HGF secretion and albumin concentrations deserve attention.

**CONCLUSION**

Dogs with MAPSS should continue to receive a diet based on high-quality proteins as a source of BCAA, and a good nutritional status should be pursued to minimize clinical signs related to HE. In studies in humans with severe liver disease, various positive effects of BCAA supplementation have been confirmed; not only are HE signs abated and albumin synthesis stimulated, there are also indications for liver regeneration. Oral leucine seems to be particularly promising because it might stimulate HGF secretion. Up till now, there are no similar studies in dogs with liver disease, let alone in dogs with MAPSS. However, the positive results in human medicine certainly appeal for further investigation in those dogs.

A life-long treatment with systemic HGF supplementation may potentially ensure sustained liver growth, despite the abnormal portal circulation in dogs with MAPSS. However, repeated intravenous supplementation of HGF is not an appropriate clinical approach in veterinary medicine. Administration of drugs that stimulate endogenous HGF secretion may form an interesting alternative. In a second step, it should still be demonstrated whether long term administration of HGF will also ameliorate liver function in addition to liver growth.

**CONFLICT OF INTEREST**

No conflicts of interest have been declared. No financial or other support was used in this study.

**REFERENCES**


García-Pras, E., Gallego, J., Coch, L., Mejías, M., Fernan-
Kato, M., Yoshida, T., Moriwaki, H., Mut, Y.
Ishiki, Y., Ohnishi, H., Muto, Y., Matsumoto, K., Naka
Ishii, T., Sato, M., Sudo, K., Suzuki, M., Nakai, H., Hishida,
Howe, L.M., Boothe, H.W. Jr., Miller, M.W., Boothe, D.M.
Hou, W., Sanyal, A.J. (2009). Ascites: Diagnosis and man
agement of chronic portal systemic encephalopathy. *Gut* 66,
1306-1320.
lose, rifaximin or branched chain amino acids for hepatic encephalopathy: what is the evidence? *Metabolic Brain Disease* 28, 221-225.
cial effect on manifestations of hepatic encephalopathy in a systematic review with meta-analyses of randomized controlled trials. *The Journal of Nutrition* 143, 1263-
1268.
ptophan binding to albumin and the competition with in-
dole-3-acetic acid. *Journal of Investigative Medicine* 48,
274-280.
Holeczek, M., Kandar, R., Sispera, L., Kovarik, M. (2011). Acute hyperammonemia activates branched-chain amino acid catabolism and decreases their extracellular concentra-
Hou, W., Sanyal, A.J. (2009). Ascites: Diagnosis and manage-
Ishii, T., Sato, M., Sudo, K., Suzuki, M., Nakai, H., Hishida,
Niwa, T., Umezu, K., Yuasa, S. (1995). Hepatocyte growth factor stimulates liver regeneration and elevates blood protein level in normal and partially hepa-
Ishiki, Y., Ohnishi, H., Muto, Y., Matsumoto, K., Naka-
mura, T. (1992). Direct evidence that hepatocyte growth factor is a hepatotrophic factor for liver regeneration and has a potent antihepatic effect in vivo. *Hepatology* 16,
1227-1235.
physiology and clinical consequences. *Compendium on Continuing Education for the Practicing Veterinarian* 9,
741-748.
Joyeux, H., Matias, J., Saint-Aubert, B., Astre, C., Gout-
288.
Kim, S.J., Kim, D.G., Lee, M.D. (2011). Effects of branched-chain amino acid infusions on liver regeneration and plasma amino acid patterns in partially hepate-
tectomized rats. *Hepatogastroenterology* 58, 1280-1285.
Kim, W.H., Matsumoto, K., Bessho, K., Nakamura, T. (2005). Growth inhibition and apoptosis in liver myo-
fibroblasts promoted by hepatocyte growth factor leads to resolution from liver cirrhosis. *American Journal of Pathology* 166, 1017-1028.
Kuwahata, M., Yoshimura, T., Sawai, Y., Amano, S., To-
723.
blind, casein-controlled study. *Journal of Hepatology* 11,
92-101.
Merli, M., Riggio, O. (2009). Dietary and nutritional indi-
cations in hepatic encephalopathy. *Metabolic Brain Disease* 24, 211-221.
Mizuno, S., Nakamura, T. (2007). Hepatocyte growth fac-
tor: a regenerative drug for acute hepatitis and liver cir-
Nakamura, T., Mizuno, S. (2010). The discovery of He-
anocytotate Growth Factor (HGF) and its significance for cell biology, life sciences and clinical medicine. In: *Proceed-
ings of the Japan Academy, Series B Physical and Bio-
logical Sciences* 86, 588-610.
fication and characterization of hepatocyte growth factor from serum of hepatectomized rats. *Biochemical and Biophysical Research Communications* 122, 1450-1459.
Nakamura, T., Nishizawa, T., Hagiy, M., Seki, T., Shimoni-
esthesia* 85, 599-610.
Okabayashi, T., Shina, Y., Sumiyoshi, T., Kozuki, A.,


